X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to support the clinical advancement of Korro's lead product KRRO-110 for treating patients suffering from alpha-1 antitrypsin deficiency.
Lead Product(s): KRRO-110
Therapeutic Area: Genetic Disease Product Name: KRRO-110
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Deep Track Capital
Deal Size: $70.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 18, 2024
Details:
KRRO-110 is based on Korro’s proprietary RNA editing platform, OPERA™. It is being evaluated in preclinical studies for the treatment of Alpha-1 Antitrypsin Deficiency.
Lead Product(s): KRRO-110
Therapeutic Area: Genetic Disease Product Name: KRRO-110
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
Details:
KRRO-110 is an oligonucleotide restorator, which works by targeting A1AT protein, it is being investigated for the treatment of Alpha-1 Antitrypsin Deficiency.
Lead Product(s): KRRO-110
Therapeutic Area: Genetic Disease Product Name: KRRO-110
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Details:
The combined company will focus on the advancement of Korro Bio’s portfolio of RNA editing programs including, OPERA platform which harnesses the body’s natural base editing system, specifically ADAR, to make targeted edits to a single RNA base.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Frequency Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger November 03, 2023
Details:
The combined company will focus on the advancement of Korro Bio’s portfolio of RNA editing programs including, OPERA platform which harnesses the body’s natural base editing system, specifically ADAR, to make targeted edits to a single RNA base.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Recipient: Frequency Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger July 14, 2023
Details:
The Collaboration to combine Korro’s RNA editing technology with Genevant’s industry-leading LNP technology to develop a differentiated therapeutic option for patients with Alpha-1 Antitrypsin Deficiency (AATD).
Lead Product(s): RNA-based Therapeutic
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Genevant Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 07, 2023
Details:
The financing will enable Korro to advance its lead program in development for patients with Alpha-1 Antitrypsin Deficiency (AATD), an inherited genetic disorder leading to liver and lung disease with RNA editing platform.
Lead Product(s): Genetic Medicine
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eventide Asset Management
Deal Size: $116.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 05, 2022
Details:
This financing enables Korro to advance its lead program to IND filing and establish a broad portfolio of innovative RNA editing therapies. Korro’s OPERA platform, harnesses the body’s natural base editing system, specifically ADAR to make targeted edits to a single RNA base.
Lead Product(s): RNA editing therapies
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Wu Capital
Deal Size: $91.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
